Skip to main content
MedPathMedPath Home
Clinical Trials/NCT02517281
NCT02517281
Completed
N/A

Prospective Clinical and Biologic Study of Secondary Cutaneous Effects in Targeted Cancer Therapies

Gustave Roussy, Cancer Campus, Grand Paris1 site in 1 country141 target enrollmentJuly 12, 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cancer
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Enrollment
141
Locations
1
Primary Endpoint
Number of clinical secondary effects bind to targeted therapies
Status
Completed
Last Updated
last month
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The aim of the study is to do a descriptive analysis of the cutaneous toxicity observed in patients treated using targeted therapies in order to have a better understanding of the skin pathophysiology.

Registry
clinicaltrials.gov
Start Date
July 12, 2011
End Date
June 22, 2022
Last Updated
last month
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Patients with cancer beginning a targeted therapy
  • •Patients able to follow the protocol
  • •Age \>/= 18 years old
  • •Signed inform consent

Exclusion Criteria

  • •Patient unable to follow the protocol, having a non cooperative behavior or unable to come to follow up visits or unable to complete the study
  • •Pregnant or breastfeeding woman

Outcomes

Primary Outcomes

Number of clinical secondary effects bind to targeted therapies

Time Frame: Every 28 days up to 5 years

Dermatological exam including questionnaire, clinical examination and photographies

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary SyndromeMycosis FungoidesSézary Syndrome
NCT02822586Virginia Commonwealth University5
Completed
N/A
To Investigate the Cutaneous and Ocular Local Tolerance of Two Cosmetic Facial Cleanser in Healthy Females With Sensitive SkinSkin Care
NCT03172364GlaxoSmithKline122
Terminated
Phase 1
Hypertrophic Scar Prevention by Novel Topical Gel ApplicationHypertrophic Scar
NCT03403621Mayo Clinic6
Completed
Phase 2
A phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in EGFR-mutated advanced non-small cell lung cancernon-small cell lung cancer
JPRN-jRCTs071190015Takayama Koichi41
Completed
Phase 2
5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial OligometastasesSolid Tumors With Oligometastatic Spread
NCT01761929University Health Network, Toronto138